Syndax Memproyeksikan Pendapatan Bersih Puncak Revuforj di AS Melampaui $2 Miliar Menjelang Hasil Uji Axatilimab pada Kuartal Keempat (NASDAQ:SNDX)
· seekingalpha.com
Ringkasan laporan laba Q2 2026 Syndax (SNDX): Penjualan Revuforj/Niktimvo, prospek puncak $2 miliar lebih, katalis Q4, dan ketersediaan kas (cash runway).
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...